Comparative Pharmacology
Head-to-head clinical analysis: CYCLOGYL versus CYCLOPENTOLATE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOGYL versus CYCLOPENTOLATE HYDROCHLORIDE.
CYCLOGYL vs CYCLOPENTOLATE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Blocks muscarinic acetylcholine receptors (M1-M5), inhibiting parasympathetic nerve impulses that cause constriction of the ciliary muscle and sphincter muscle of the iris, resulting in cycloplegia (ciliary muscle paralysis) and mydriasis (pupil dilation).
Antimuscarinic agent; blocks acetylcholine at muscarinic receptors in the sphincter and ciliary muscles of the iris, producing mydriasis and cycloplegia.
1-2 drops of 0.5% or 1% solution in conjunctival sac, may repeat in 5-10 minutes if needed, up to every 4-6 hours.
1-2 drops of 0.5-1% solution, repeat in 5-10 minutes if necessary; or 0.1-0.5 mL of 1% solution subconjunctivally.
None Documented
None Documented
Terminal elimination half-life is approximately 0.5 to 0.75 hours in adults; in children, it may be slightly shorter. Clinical context: short half-life allows repeated administration for mydriasis and cycloplegia.
Terminal elimination half-life is approximately 2.5 hours in adults; shorter in children (~1-2 hours) and prolonged in elderly or hepatic impairment.
Renal excretion of unchanged drug accounts for less than 5% of elimination; the majority is metabolized in the liver and excreted in urine as metabolites. Biliary/fecal excretion is minimal (<2%).
Renal excretion of unchanged drug and metabolites accounts for approximately 60-70% of elimination; the remainder is biliary/fecal.
Category C
Category C
Ophthalmic Anticholinergic
Ophthalmic Anticholinergic